Participant disposition and baseline demographics
cardiac arrest
DISEASE, CARDIAC ARREST, BREAST CANCER
A total of 106 participants were screened for eligibility, and 84 were randomized to treatment (Patient disposition. A total of 106 participants were screened, and 84 met eligibility criteria, were enrolled in the trial, and randomized to treatment. Two participants randomized to TransCon PTH discontinued the trial before receiving treatment: one withdrew consent, and one withdrew due to thyroid cancer recurrence. Sixty‐one participants in the TransCon PTH and 21 participants in the placebo group received ≥1 blinded treatment and comprised the intent‐to‐treat population. During the trial, one participant in the TransCon PTH group experienced a fatal cardiac arrest (unrelated to the study drug), and 2 withdrew from the placebo group: one withdrew consent, and one withdrew due to breast cancer. A total of 79 participants completed the blinded treatment through week 26.Baseline Demographics, Disease Characteristics, and SupplementationAbbreviations: PTH = parathyroid hormone; SD = standard deviation.